PURPOSE: To study the efficacy, safety, and outcome of standardized second-line anti-TB treatment of multidrug-resistant tuberculosis (MDR-TB) during pregnancy focusing on maternal and perinatal outcomes.
METHODS: Prospective study conducted to evaluate the outcomes of standardized MDR-TB treatment during pregnancy in patients referred to NRITLD from 2003 to 2008. Outcomes are investigated in two categories, namely, maternal and neonatal.
RESULTS: Five MDR-TB patients whilst receiving standardized anti-TB regimen became pregnant. We did not change the regimen and all of them did not reveal any adverse effects throughout pregnancy and delivery. No adverse effect occurred for the mothers and the neonates, either.
CONCLUSION: Treatment of MDR-TB in pregnancy with standardized second-line regimen could be safe and the rate of successful outcome is acceptable.
CLINICAL IMPLICATIONS: Although recommendations for the treatment of pregnant women with pulmonary TB are available, there is no unique guideline for treatment of MDR-TB during pregnancy. The response to treatment is not clear and it has not been yet elucidated which drugs are safe during pregnancy in these patients. In this study all patients received the same standardized regimen of medications. Accordingly, evaluation of patients’ response to treatment and side effects of the treatment could be readily evaluated and compared in a uniform format.
DISCLOSURE: Ahmadreza Moradi, No Financial Disclosure Information; No Product/Research Disclosure Information